Zynerba Pharmaceuticals (ZYNE)

[Leonard McKinley]

Today looks like the turn. The volume is low. There are no more sellers. The buyers are scared but they are creeping back and pushing up the stock. This will accelerate, I suspect, and push the stock up to some new and stable level. I doubt that that level is the previous $11.3. I think more like $9.5 or $10. Serious damage has been done, and OVID did report a competitive product. Also, Zyne has to find new shareholders to replace all of the poor slobs who got shaken out. This has been a very painful interlude for us, the longs. Next year should be very good, IMO. Fragile X and ASD are very big things, and Zyne will have important therapeutic effect to report for both of them, I believe.